Action PMGM PRIVETERRA ACQUISITION CORP. II
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Priveterra Acquisition Corp. II

Actions

PMGM

US8765451047

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 16/04/2024 		Varia. 5j. Varia. 1 janv.
11,21 USD +1,72% Graphique intraday de Priveterra Acquisition Corp. II 0,00% +2,00%
2023 Priveterra Acquisition Corp. II annonce ses résultats pour le troisième trimestre et les neuf mois clos le 30 septembre 2023 CI
2023 Priveterra Acquisition Corp. II présente ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
AEON Biopharma Announces Redemption of Public Warrants - March 29, 2024
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
AEON Biopharma Announces Redemption of Public Warrants
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
Priveterra Acquisition Corp. II Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
AEON Biopharma Reports Third Quarter 2023 Financial Results
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
Priveterra Acquisition Corp. II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Tastemaker Acquisition Corp. has Changed its Name to Priveterra Acquisition Corp. II
Tastemaker Acquisition Corp. Announces the Resignation of Christopher Bradley as Chief Financial Officer
Tastemaker Acquisition Corp. Announces Board Changes
Tastemaker Acquisition Corp. Announces CEO Changes
Tastemaker SPAC calls off nearly $1 bln planned merger with Quality Gold
Tastemaker Acquisition : Announces Termination of Business Combination Agreement - Form 8-K
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PMGM
  4. Actualités Priveterra Acquisition Corp. II
  5. Autres langues